Patient Related Outcome Measures (Feb 2019)

Lubiprostone in the treatment of chronic idiopathic constipation: an update on health-related quality of life and patient-reported outcomes

  • Hayat M,
  • Zia H,
  • Nusrat S

Journal volume & issue
Vol. Volume 10
pp. 43 – 47

Abstract

Read online

Maham Hayat,1 Hassaan Zia,2 Salman Nusrat2 1Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; 2Section of Digestive Diseases & Nutrition, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA Abstract: Chronic idiopathic constipation, if inadequately treated, can be bothersome with a detrimental effect on patients’ quality of life (QOL). This may also result in frequent health care visits, increasing the burden of this ailment’s medical cost. Management strategies, focused on lifestyle changes, include increased exercise, a high-fiber diet, and toilet training. Pharmacologic options include fiber supplementation, laxatives, serotonergic agents, and prosecretory agents such as lubiprostone. In this review, we were able to conclude that lubiprostone, when used for chronic idiopathic constipation, has a significantly beneficial effect on both patients’ symptoms and their QOL. In multiple randomized controlled trials, it has been found to have increased the number of spontaneous bowel movements at different time endpoints. Corresponding improvements were also observed for abdominal bloating, discomfort, stool frequency, and straining symptoms among patients. Keywords: functional, gastrointestinal disorders, spontaneous bowel movements, secretory agents, abdominal pain, cost-effectiveness  

Keywords